作者:Patrick A. M. Jansen、Danique A. van der Krieken、Peter N. M. Botman、Richard H. Blaauw、Lorenzo Cavina、Eline M. Raaijmakers、Erik de Heuvel、Julia Sandrock、Lian J. Pennings、Pedro H. H. Hermkens、Patrick L. J. M. Zeeuwen、Floris P. J. T. Rutjes、Joost Schalkwijk
DOI:10.1038/s41429-019-0196-6
日期:2019.9
The emergence of multidrug resistant bacteria has prioritized the development of new antibiotics. N-substituted pantothenamides, analogs of the natural compound pantetheine, were reported to target bacterial coenzyme A biosynthesis, but these compounds have never reached the clinic due to their instability in biological fluids. Plasma-stable pantothenamide analogs could overcome these issues. We first synthesized a number of bioisosteres of the prototypic pantothenamide N7-Pan. A compound with an inverted amide bond (CXP18.6-012) was found to provide plasma-stability with minimal loss of activity compared to the parent compound N7-Pan. Next, we synthesized inverted pantothenamides with a large variety of side chains. Among these we identified a number of novel stable inverted pantothenamides with selective activity against Gram-positive bacteria such as staphylococci and streptococci, at low micromolar concentrations. These data provide future direction for the development of pantothenamides with clinical potential.
多药耐药细菌的出现使得新抗生素的开发变得尤为重要。N取代的泛酰胺作为天然化合物泛酰胺的类似物,已被报道能靶向细菌辅酶A的生物合成,但由于在生物液体中不稳定,这些化合物从未进入临床。稳定的泛酰胺类似物可以克服这些问题。我们首先合成了多种原型泛酰胺N7-Pan的生物等排体。发现一种反向酰胺键的化合物(CXP18.6-012)在与母体化合物N7-Pan相比时,能够提供血浆稳定性且活性损失最小。接下来,我们合成了具有多种侧链的反向泛酰胺。在这些化合物中,我们识别出了一些新型的稳定反向泛酰胺,其对革兰氏阳性细菌如金黄色葡萄球菌和链球菌表现出选择性活性,浓度在低微摩尔范围。这些数据为未来具有临床潜力的泛酰胺的开发提供了方向。